Business Wire (Tue, 1-Sep 9:03 AM ET)
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 17-Aug 9:16 PM ET)
Business Wire (Mon, 17-Aug 12:57 PM ET)
Globe Newswire (Sat, 8-Aug 8:43 AM ET)
Are UTZ, VEEE, CRNX Obtaining Fair Deals for their Shareholders?
PRNewswire (Thu, 6-Aug 10:31 PM ET)
PRNewswire (Thu, 6-Aug 4:33 PM ET)
Are ACA, CRNX, LEG Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 3-Aug 7:39 PM ET)
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Mon, 3-Aug 4:05 PM ET)
PRNewswire (Mon, 3-Aug 3:21 PM ET)
Are UTZ, CRNX, SOLS Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 28-Jul 10:50 AM ET)
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Crinetics Pharmaceuticals trades on the NASDAQ stock market under the symbol CRNX.
As of September 15, 2026, CRNX stock price was flat at $84.95 with million shares trading.
CRNX has a beta of 1.48, meaning it tends to be more sensitive to market movements. CRNX has a correlation of 0.05 to the broad based SPY ETF.
CRNX has a market cap of $9.01 billion. This is considered a Mid Cap stock.
Last quarter Crinetics Pharmaceuticals reported $25 million in Revenue and -$1.14 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.08.
In the last 3 years, CRNX traded as high as $85.01 and as low as $24.10.
The top ETF exchange traded funds that CRNX belongs to (by Net Assets): VTI, VB, VBK, VXF, VTWO.
CRNX has outperformed the market in the last year with a price return of +149.9% while the SPY ETF gained +16.3%. CRNX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +146.4% and 0.0%, respectively, while the SPY returned +2.3% and -1.3%, respectively.
CRNX support price is $84.90 and resistance is $85.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRNX shares will trade within this expected range on the day.